Sanofi's recent profit surge, driven by its blockbuster drug Dupixent, highlights a powerful investment theme. This idea focuses on innovative pharmaceutical companies with high-growth drugs and the broader ecosystem that supports their success.
Published on October 24
These companies are developing cutting-edge treatments for diseases that currently have limited options. When successful, these innovations can create entirely new markets and generate billions in revenue.
Many of these firms have multiple drugs in development, meaning success isn't dependent on just one treatment. A strong pipeline can provide sustained growth opportunities for years to come.
This group includes both established pharmaceutical giants and innovative biotech pioneers. These companies often set the standard for treatment in their respective therapeutic areas, commanding premium pricing for their breakthrough drugs.
Sanofi's recent success with Dupixent demonstrates how a single blockbuster drug can transform a pharmaceutical company's fortunes. This group focuses on innovative biopharma companies developing breakthrough therapies in oncology, immunology, and rare diseases, plus the supporting ecosystem that helps bring these treatments to market.
These companies operate in high-risk, high-reward areas of medicine, developing novel treatments that can generate substantial revenues for years. The group includes both established pharmaceutical giants and emerging biotech firms, offering exposure to different stages of drug development and commercialisation.
Each company was selected for its potential to develop or benefit from blockbuster drugs. They represent leaders in cutting-edge medical research, companies with promising drug pipelines, or firms that support the pharmaceutical supply chain through innovative technologies and manufacturing capabilities.
Market capitalisation breakdown for the user's stock basket 'Pharma's Blockbuster Bets'.
SNY: $122.84B
VRTX: $109.29B
BMY: $90.66B
Get the full story on this Basket. Read our detailed article on its risks and potential.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
Home Depot's recent earnings beat highlights consistent consumer spending on smaller household repair and maintenance projects. This ongoing trend presents promising opportunities for various home improvement retailers and building material suppliers.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
VERTEX PHARMACEUTICAL
VRTX
Current Price
$549.66
Vertex is a major biotechnology firm with a portfolio of successful drugs, particularly for cystic fibrosis, and a robust pipeline, aligning with the ...
Vertex is a major biotechnology firm with a portfolio of successful drugs, particularly for cystic fibrosis, and a robust pipeline, aligning with the theme of innovative, high-growth pharmaceuticals.
Bristol Myers Squibb
BMY
Current Price
$67.62
Bristol-Myers Squibb is a global biopharmaceutical leader with a strong portfolio of blockbuster drugs in oncology and immunology, representing the ki...
Bristol-Myers Squibb is a global biopharmaceutical leader with a strong portfolio of blockbuster drugs in oncology and immunology, representing the kind of innovative company the theme focuses on.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+6.29%
On average, analysts expect assets in this group to grow 6.29% over the next year.
13 of 15 assets in this group are rated Buy by professional analysts.
